Drugs / Bevespi
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05607719 | Apr 2023 → Jul 2026 overdue | chronic obstructive pulmonary disease | University of Miami | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05495698 | Dec 2022 → Dec 2026 expected | chronic obstructive pulmonary disease | Franciscus Gasthuis | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevespi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607719 ↗ |
| Route | Inhaled | “multi-inhaler triple therapy (Qvar + Bevespi)” NCT05495698 ↗ |